Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients

被引:2
|
作者
Gualano, Bruno [1 ,2 ]
Saad, Carla G. S. [3 ]
Sieczkowska, Sofia M. [1 ]
Lemes, Italo Ribeiro [1 ]
da Silva, Rafael Pires [1 ]
Pinto, Ana J. [1 ,4 ]
Mazzolani, Bruna C. [1 ]
Smaira, Fabiana, I [1 ]
Gil, Saulo [1 ]
Oliveira-Junior, Gersiel [1 ]
Aikawa, Nadia E. [3 ]
Medeiros-Ribeiro, Ana C. [3 ]
Silva, Clovis A. [3 ,5 ]
Yuki, Emily F. N. [3 ]
Pasoto, Sandra G. [3 ]
Pereira, Rosa Maria R. [3 ]
Shinjo, Samuel K. [3 ]
Andrade, Danieli C. O. [3 ]
Sampaio-Barros, Percival D. [3 ]
Roschel, Hamilton [1 ]
Bonfa, Eloisa [3 ]
机构
[1] Univ Sao Paulo, Fac Med FMUSP, Sch Phys Educ & Sport, Div Rheumatol,Appl Physiol & Nutr Res Grp, Sao Paulo, Brazil
[2] Univ Sao Paulo, Food Res Ctr, Sao Paulo, Brazil
[3] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Div Rheumatol, Sao Paulo, Brazil
[4] Univ Colorado, Sch Med, Metab & Diabet & Anschutz Hlth & Wellness Ctr, Div Endocrinol, Anschutz Med Campus, Aurora, CO USA
[5] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Crianca & Adolescente,Pediat Rheumatol Unit, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
COVID-19; immunosuppression; physical activity; resistance exercise; Sinovac-CoronaVac; ECCENTRIC EXERCISE; PHYSICAL-ACTIVITY; RESPONSES; EFFICACY; ANTIBODY; ADJUVANT;
D O I
10.1152/japplphysiol.00015.2022
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. NEW & NOTEWORTHY We tested the role of exercise as an adjuvant to a booster of a COVID-19 vaccine. Immunocompromised patients were immunized after an acute bout of exercise or not. Patients exhibited an excellent immunogenicity in response to
引用
收藏
页码:682 / 688
页数:7
相关论文
共 50 条
  • [1] Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis
    Li, Haolong
    Wang, Xu
    Wang, Siyu
    Feng, Xinxin
    Wang, Li
    Li, Yongzhe
    HELIYON, 2024, 10 (07)
  • [2] Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
    Han, Shanshan
    Yang, Yuping
    Wang, Tingrui
    Song, Rui
    Hu, Daixing
    Peng, Mingli
    Lin, Zijing
    Deng, Qin
    Ren, Hong
    Ming, Jia
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [3] Safety and Immunogenicity Outcomes of an Inactivated Viral Vaccine against SARS-CoV-2 (Covaxin®)
    Sinha, Parul
    Gupta, Megha
    Vijayvergia, Varunika
    Jain, Sushil Kumar
    Jain, Dinesh Kumar
    Gupta, Sandeep
    Rathore, Monika
    Vyas, Nitya
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022, 16 (09) : DC12 - DC17
  • [4] Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China
    Tung, Tao-Hsin
    Lin, Xiao-Qing
    Chen, Yan
    Zhang, Mei-Xian
    Zhu, Jian-Sheng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [5] Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
    Kandeil, Ahmed
    Mostafa, Ahmed
    Hegazy, Rehab R.
    El-Shesheny, Rabeh
    El Taweel, Ahmed
    Gomaa, Mokhtar R.
    Shehata, Mahmoud
    Elbaset, Marawan A.
    Kayed, Ahmed E.
    Mahmoud, Sara H.
    Moatasim, Yassmin
    Kutkat, Omnia
    Yassen, Noha N.
    Shabana, Marwa E.
    GabAllah, Mohamed
    Kamel, Mina Nabil
    Abo Shama, Noura M.
    El Sayes, Mohamed
    Ahmed, Amira N.
    Elalfy, Zahraa S.
    Mohamed, Bassim M. S. A.
    Abd El-Fattah, Safa N.
    El Hariri, Hazem Mohamed
    Abdel Kader, Mona
    Azmy, Osama
    Kayali, Ghazi
    Ali, Mohamed A.
    VACCINES, 2021, 9 (03) : 1 - 15
  • [6] Effect of Inactivated Vaccines Against SARS-CoV-2 on Immunogenicity Outcome
    Ma, Yuke
    Du, Yukuan
    Yang, Jingnan
    Wang, Huichao
    Lin, Xuhong
    DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2025, 19
  • [7] Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
    Assawasaksakul, Theerada
    Sathitratanacheewin, Seelwan
    Vichaiwattana, Preeyaporn
    Wanlapakorn, Nasamon
    Poovorawan, Yong
    Kittanamongkolchai, Wonngarm
    RMD OPEN, 2021, 7 (03):
  • [8] Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?
    Kara, Ertan
    Tanir, Ferdi
    Demirhindi, Hakan
    Mete, Burak
    Kibar, Filiz
    Cetiner, Salih
    Candevir, Aslihan
    Inaltekin, Ayse
    MIKROBIYOLOJI BULTENI, 2022, 56 (03): : 566 - 573
  • [9] The immunogenicity of Alum plus CpG adjuvant SARS-CoV-2 inactivated vaccine in mice
    Yang, Jie
    Li, Boran
    Yang, Dongsheng
    Wu, Jie
    Yang, Anna
    Wang, Wenhui
    Lin, Fengjie
    Wan, Xin
    Li, YuWei
    Chen, Zhuo
    Lv, Shiyun
    Pang, Deqin
    Liao, Wenbo
    Meng, Shengli
    Lu, Jia
    Guo, Jing
    Wang, Zejun
    Shen, Shuo
    VACCINE, 2023, 41 (41) : 6064 - 6071
  • [10] Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
    Aikawa, Nadia Emi
    Kanda Kupa, Leonard de Vinci
    Medeiros-Ribeiro, Ana Cristina
    Schahin Saad, Carla Goncalves
    Neves Yuki, Emily Figueiredo
    Pasoto, Sandra Gofinet
    Rojo, Priscila Tagliaferro
    Rodrigues Pereira, Rosa Maria
    Shinjo, Samuel Katsuyuki
    Sampaio-Barros, Percival Degrava
    Oliveira Andrade, Danieli Castro
    Radu Halpern, Ari Stiel
    Fuller, Ricardo
    Carlos Souza, Fernando Henrique
    Noronha Guedes, Lissiane Karine
    Assad, Ana Paula Luppino
    Bertacini de Moraes, Julio Cesar
    Ugolini Lopes, Michelle Remiao
    de Oliveira Martins, Victor Adriano
    Betancourt, Lorena
    Ribeiro, Carolina Torres
    Sales, Lucas Peixoto
    Bertoglio, Isabela Maria
    Nazario Bonoldi, Virginia Lucia
    Pinheiro Mello, Renata Lys
    Moreira Balbi, Gustavo Guimaraes
    Christovam Sartori, Ana Marli
    Antonangelo, Leila
    Silva, Clovis Artur
    Bonfa, Eloisa
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (07) : 1036 - 1043